Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.

ABSTRACT:

Background

Recent studies have shown that approximately 20% of patients have 4-5 year progression free survival (PFS) on BRAF/MEK inhibitors. The long-term safety and efficacy in these patients with more durable responses have not been studied.

Methods

This retrospective multicenter cohort study assessed response, progression, and adverse events in patients from eight institutions in four countries with >4-year PFS following BRAF/MEK inhibitors.

Results

Among 146 patients, 112 (76.7%) remained progression-free at median follow-up of 7.8 years from treatment start; 131 (89.7%) were alive. Among progressors (n = 34), 21 (62%) were on treatment at progression. Among those who discontinued treatment for reasons other than progression (toxicity, preference, etc.) (n = 68,

SUBMITTER: Goodman RS 

PROVIDER: S-EPMC10843257 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature